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Quetiapine extended release (XR) and lithium are treatments with proven efficacy in acute mania. This randomized
study evaluated the efficacy and safety of lithium or placebo as add-on to quetiapine XR in adult patients with manic
or mixed symptoms of bipolar I disorder. In this 6-week, double-blind study (Trial D144AC00003), adult patients with
DSM-IV-TR-diagnosed bipolar I disorder (current episode manic or mixed), a Young Mania Rating Scale (YMRS) total
score ≥20, and score ≥4 on two of four core YMRS items were administered quetiapine XR (400 to 800 mg/day) and
randomly assigned to receive add-on lithium (600 to 1,800 mg/day) or placebo. The primary efficacy end point was
change in the YMRS total score from baseline to day 43, analyzed using a mixed-model for repeated measures
(MMRM) approach. Secondary efficacy and safety end points were also measured. Rating scales were administered by
trained staff. Three hundred fifty-six patients treated with quetiapine XR were randomized to add-on lithium (n = 173)
or placebo (n = 183). Two hundred ninety-one patients (81.7%) completed the study. At day 43, least squares mean
change in YMRS total score was −22.8 for add-on lithium and −20.1 for add-on placebo, a statistically significant
treatment group difference of −2.69 (p < 0.001). On secondary measures, add-on lithium was associated with significant
improvements in response, remission, illness severity, and overall illness versus add-on placebo (p < 0.05). The number
needed to treat was 9.1 for response and 7.9 for remission for add-on lithium compared with add-on placebo. Lithium
in combination with quetiapine XR was generally well tolerated, with a similar profile to quetiapine XR in combination
with placebo. The addition of lithium to quetiapine XR therapy was associated with significantly greater efficacy than
placebo as add-on and was generally well tolerated in patients with acute bipolar I mania. This study was registered
under Clinicaltrials.gov Identifier NCT00931723.
Keywords: Bipolar mania; Lithium; Quetiapine XRBackground
Bipolar disorder is a complex, debilitating illness that typic-
ally follows a chronic and recurrent course. Manic, de-
pressed, or mixed symptoms range in severity and rate
of onset and in their most extreme forms require
hospitalization (Sanchez-Moreno et al. 2009).
Given the severe impact and rapid onset of manic symp-
toms in many patients, prompt and effective control of* Correspondence: Michel.Bourin@univ-nantes.fr
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in any medium, provided the original work is psymptoms is a primary treatment goal (Garlow 2008; Oral
2005). Guidelines typically recommend lithium, divalproex,
or an atypical antipsychotic in the treatment of acute
mania, frequently as monotherapy initially, with combin-
ation therapy in cases of inadequate response (Connolly
and Thase 2011; Goodwin 2009; Grunze et al. 2009; Nivoli
et al. 2011; Yatham et al. 2009). Guidelines also recom-
mend combination therapy as first-line treatment for se-
vere manic symptoms (Goodwin 2009; Grunze et al. 2009;
Nivoli et al. 2011). However, there is a lack of evidence to
support the efficacy and safety of many combination ther-
apies, and not all agents demonstrating antimanic efficacyn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tolerability when used in combination (Brooks et al. 2011;
Geoffroy et al. 2012; Sachs and Gardner-Schuster 2007;
Smith et al. 2007).
Quetiapine extended release (quetiapine XR) demon-
strates efficacy as monotherapy in acute mania (Cutler et al.
2011) and bipolar depression (Suppes et al. 2010). Yatham
et al. (2004) previously reported that quetiapine immediate
release (IR) added to lithium or divalproex provided super-
ior efficacy in treating mania when compared with lithium
or divalproex alone. The potential benefits of adding
lithium to quetiapine XR have not previously been investi-
gated. The current study compared the efficacy and safety
of lithium versus placebo as add-on to quetiapine XR in
adults with bipolar I disorder with a current or recent epi-
sode of severe manic or mixed symptoms.
Methods
Study design
This was a 6-week, multicenter, double-blind, randomized,
parallel-group placebo-controlled study (Trial D144AC00003;
Clinicaltrials.gov ID: NCT00931723), conducted at 38
study centers in eight countries (Belgium, Bulgaria, Germany,
India, Poland, Russia, South Africa, and Ukraine) between
June 24, 2009 and November 22, 2010. The study included
an enrollment period (with medication washout for 7
to 28 days, according to medication) and a 6-week treat-
ment period, when quetiapine XR was administered as flex-
ible dose to all patients. Patients were randomly assigned
in a 1:1 ratio to receive, in addition, either flexible-dose
lithium or placebo at the start of treatment. Following
mandatory hospitalization during randomization, patients
were permitted to continue study treatment as outpatients.
The study was performed in agreement with the ethical
principles of the Declaration of Helsinki and was consist-
ent with the International Conference on Harmonization
(ICH)/Good Clinical Practice (GCP). Written informed
consent was provided by all patients.
Patient population
Males or females aged 18 to 65 years with a Diagnostic and
Statistical Manual for Metal Disorders, Fourth Edition,
Text Revision (DSM-IV-TR) diagnosis of bipolar I dis-
order (most recent episode manic or mixed) (American
Psychiatric Association 2000), confirmed by the Structured
Clinical Interview for DSM-IV (First et al. 2007), were eli-
gible for inclusion. Patients were required to have a Young
Mania Rating Scale (YMRS) (Young et al. 1978) total score
≥20 and ≥4 on two of four core items (irritability, speech,
content, disruptive/aggressive behavior), a Clinical Global
Impressions for Bipolar Disorder (CGI-BP) (Spearing et al.
1997) score ≥4 (i.e., moderately ill), and to have experi-
enced ≥1 manic or mixed episode (other than the current
episode) in the past 5 years.Key exclusion criteria included current DSM-IV-TR Axis
I disorders other than bipolar mania; >8 mood episodes
within the previous 12 months; mania-like syndrome asso-
ciated with a medical condition or treatment, substance
abuse, or withdrawal; continuous hospitalization for an
acute episode of bipolar mania for >3 weeks before
randomization; current substance dependence or abuse;
current serious suicidal or homicidal risk; or history of
nonresponse to study treatments.
The use of an antipsychotic other than quetiapine, mood
stabilizer, antidepressant, anxiolytic, hypnotic, other psycho-
active drug, or inducer/inhibitor of cytochrome P 3A4
enzymes was prohibited within 7 to 28 days before
randomization. Nonpsychoactive and anticholinergic med-
ications were allowed during the study, as were zolpidem
tartrate (maximum 10 mg/day), zaleplon (20 mg/day),
zopiclone (7.5 mg/day), chloral hydrate (1 g/day), and
lorazepam (2 mg/day).
Study treatments
Open-label quetiapine XR was administered once-daily
in the evening, at a starting dose of 300 mg/day on day
1, increasing to 600 mg/day on day 2, and adjusted be-
tween 400 and 800 mg/day from day 3 onward depending
on efficacy and tolerability, in agreement with prescribing
guidelines (Seroquel XR (quetiapine fumarate) 2013). For
patients who received quetiapine prior to the study, the
existing dose was administered on day 1 and increased to
600 mg at day 2 if the previous dose was lower.
Patients were treated with lithium or placebo twice daily.
Lithium (immediate release) was administered at a starting
dose of 600 mg on days 1 and 2, increasing to 900 mg/day
on days 3 to 8. Lithium (or placebo) dosing was adjusted
(range, 600 to 1,800 mg/day) from day 9 at the discretion
of the investigator to minimize side effects or achieve tar-
get trough concentrations of 0.8 to 1.2 mEq/L. On days 8,
15, 22, 29, and 43, lithium was administered after serum
lithium sampling. On each occasion that a lithium dose
recommendation was sent for a patient randomized to
lithium, a matching sham recommendation was sent to
non-lithium patients in relation to the dose of placebo
capsule.
The lithium and placebo capsules were identical in ap-
pearance, smell, and taste to maintain blinding. In addition,
blood samples were drawn from all patients (whether
treated with lithium or placebo) on days 8, 15, 22, 29,
and 43 for determination of trough serum lithium
concentrations.
Efficacy assessments
The primary outcome measure was change in YMRS
total score from baseline to day 43. Secondary outcome
measures included changes to day 43 in scores for individ-
ual YMRS items, Clinical Global Impressions for Bipolar
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(CGI-BP-C) (Spearing et al. 1997), Positive and Negative
Syndrome Scale (PANSS) total and activation and positive
subscales (Kay et al. 1987), and Montgomery-Åsberg De-
pression Rating Scale (MADRS) (Montgomery and Asberg
1979). Response (i.e., ≥50% reduction in YMRS total score
to day 43), remission (YMRS total score ≤12 at day 43),
and improvement in overall bipolar illness (CGI-BP-C
score of ‘much’ or ‘very much’ improved overall bipolar
illness at day 43) were also assessed, using conventional
cutoff criteria (Bourin and Thibaut 2013). Rating scales
were administered by staff who were trained in their use
and who were blinded to study treatments.
Safety and tolerability assessments
Safety and tolerability assessments included treatment-
emergent adverse events (TEAEs; incidence and severity),
adverse event (AE)-related withdrawals, and changes from
baseline in vital signs, laboratory parameters, and body
weight. Extrapyramidal symptoms (EPS) were assessed by
TEAEs, changes in EPS rating scales (Simpson-Angus
Scale [SAS] (Simpson and Angus 1970), Abnormal Invol-
untary Movement Scale [AIMS] (Guy 1976), and Barnes
Akathisia Rating Scale (BARS) (Barnes 1989)), worsening
of SAS, AIMS, or BARS score category, and initiation
of anticholinergic medication for EPS. Suicidality was
assessed by TEAEs and prospective use of the Columbia-
Suicide Severity Rating Scale (C-SSRS), with mapping of
C-SSRS responses also to the Columbia-Classification Al-
gorithm for Suicide Assessment (C-CASA) (Posner et al.
2007, 2011). Other TEAEs of special interest, besides
EPS and suicidality, included somnolence, diabetes melli-
tus, QTc prolongation, neutropenia/agranulocytosis, and
depression/depressed mood.
Statistical analysis
It was estimated that 166 evaluable patients were required
in each treatment group to reject the null hypothesis of no
difference with a power of 80% when using a two-sided
t-test at an overall type I error rate of 5%, assuming a
true effect of four points on YMRS between the two
groups and a standard deviation (SD) of 9.
Efficacy analyses were performed on the modified intent-
to-treat analysis set (ITT), which included all random-
ized patients who received ≥1 dose of quetiapine XR
and lithium or placebo and had a baseline YMRS score
and ≥1 post-baseline score assessment. Group differences
in change in efficacy rating scale score were analyzed using
a mixed-model for repeated measures (MMRM) approach;
while group differences in response, remission, and overall
bipolar illness were tested using generalized estimating
equations. The robustness of the primary study analysis
was tested using the per-protocol (PP) set (i.e., all ITT
patients without major protocol violations or deviationsaffecting efficacy) and in the ITT set using robust variance
estimates, as well as by analysis of covariance (ANCOVA)
modeling using last observation carried forward (LOCF)
methodology, including baseline YMRS total score as co-
variate, treatment group as fixed effect, and centers as ran-
dom effect.
Safety variables were evaluated on the safety analysis set
(all randomized patients who received at least one dose of
study medication) and are presented using descriptive
statistics.
All statistical comparisons were based on a two-sided
test using a significance level of 5%. Analyses were per-
formed with SAS® software, Version 9.2 or higher (SAS
Institute, Cary, NC, USA).Results
Overall, 441 patients were enrolled and screened, of whom
356 received quetiapine XR and were randomized to add-
on treatment with lithium (n = 173) or placebo (n = 182)
(Figure 1). The most common reason for nonrandomiza-
tion was incorrect enrollment due to patients not meeting
the inclusion criteria (n = 57). The majority of patients
(91.0%) received study treatment as outpatients. Forty-
four of the patients (12.4%) were diagnosed with severe
mania and psychotic features at baseline.
The ITT and safety analysis sets comprised 349 and 356
patients, respectively. The PP set included 143 patients
(n = 45, add-on lithium; n = 98, add-on placebo). Failure
to achieve lithium concentrations within the target range
(n = 112 patients) was the most common protocol devi-
ation. Baseline demographics and disease characteristics
were generally similar between the treatment groups
(Table 1). Mean YMRS total scores at baseline were 29.9
and 30.0 in the add-on lithium and add-on placebo groups,
respectively, indicating a severely ill population.
Open-label quetiapine XR was administered at a mean
modal dose of 623.1 mg/day (range, 200 to 800 mg/day)
in the add-on lithium group and 669.9 mg/day (range, 300
to 900 mg/day) in the add-on placebo group. The mean
modal lithium dose was 1,085.5 mg/day (range, 300
to 1,800 mg/day). The mean serum lithium level was
0.72 mEq/L (range, 0.00 to 1.43 mEq/L) at day 43;
mean lithium levels did not differ notably during the
study (range of means, 0.64 to 0.77 mEq/L). Mean du-
rations of exposure to quetiapine XR were 38.5 days
(range, 2 to 48) in the add-on lithium group and 36.9 days
(range, 1 to 48) in the add-on placebo group; mean dura-
tions of exposure to add-on lithium or placebo were
38.6 days (range, 3 to 48) and 37.2 days (range, 2 to 48),
respectively.
The use of concomitant medications was similar between
the lithium (24.9%) and placebo (23.0%) add-on groups,
with anilides (acetaminophen) representing the most
Figure 1 Patient disposition. aOne randomized patient did not receive study treatment.
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each) (Additional file 1: Table S1).
A total of 291 (81.7%) patients completed the study,
while 65 (18.3%) patients discontinued the study prema-
turely (n = 26 (15.0%), add-on lithium; n = 39 (21.3%),
add-on placebo group), most commonly because of volun-
tary discontinuation (Figure 1). The majority of patients
were compliant with quetiapine XR (98.5%, add-on lithium;
94.4%, add-on placebo group) and with lithium (99.2%) or
placebo (96.1%).
Efficacy assessments
Primary efficacy end point
Mean YMRS total scores decreased from baseline to day
43 in both treatment groups (Figure 2). Least squares (LS)
mean (SE) reductions in YMRS total score were −22.8
(0.71) in the add-on lithium and −20.1 (0.71) in the add-
on placebo group, a significant between-group difference
of −2.69 (95% CI, −4.09 to −1.29; p < 0.001) (Table 2).
The robustness of the primary efficacy analysis was con-
firmed by supportive analyses, where significant between-
group differences at day 43 were observed in MMRM ana-
lysis of the PP set (p = 0.005), MMRM modeling of the
ITT set with robust variance estimates (p < 0.001), and
ANCOVA modeling with LOCF methodology (p = 0.001).
In post hoc analysis of patients categorized by serum
lithium level, LS mean (SE) change in YMRS total score
was −23.6 (0.79) in the ≥6 mEq/L and −21.6 (1.04) in
the <6 mEq/L group (p < 0.001 and 0.171, respectively,
vs. placebo).Secondary efficacy end points
Response (≥50% reduction in YMRS score at day 43) oc-
curred in 79.2% and 68.2% of the lithium and placebo add-
on groups, respectively, and remission (YMRS total
score ≤12 at day 43) was reported in 72.3% and 59.7%,
respectively. Between-group differences in response and
remission rates were significant in favor of add-on lithium
(p = 0.005, both). The number needed to treat was 9.1 for
response and 7.9 for remission for add-on lithium com-
pared with add-on placebo. The majority of individual
YMRS item scores were also significantly improved in the
lithium versus the placebo add-on group (Figure 3).
In post hoc analyses of patients categorized by serum
lithium level, response rates were 85.1% and 72.7%, re-
spectively, in the ≥6 and <6 mEq/L groups (p = 0.006 and
0.164, respectively, vs. placebo). Remission rates in the re-
spective lithium groups were 78.1% and 65.5% (p = 0.004
and 0.170, respectively, vs. placebo).
Add-on lithium was associated with significantly greater
LS mean reductions in CGI-BP-S (mean difference, −0.24,
p = 0.017) and CGI-BP-C (mean difference, −0.20; p =0.020)
than add-on placebo. Proportions of patients ‘much im-
proved’ or ‘very much improved’ at day 43 were similar
in the two groups (77.5% vs. 71.0%; p = 0.177).
Psychotic features and agitation and aggression, assessed
by PANSS total and positive and activation subscales, were
improved in both treatment groups, with significantly
greater improvements in the add-on lithium than add-on
placebo group (p < 0.001, 0.003, and < 0.001, for respective
scales; Table 2). Severity of depressive symptoms, measured
Table 1 Baseline demographic and clinical characteristics (safety set)
Demographic and clinical characteristics Quetiapine XR + Lithium (n = 173) Quetiapine XR + Placebo (n = 183) Total (n = 356)
Age (years)
Mean (SD) 37.9 (12.7) 38.8 (12.1) 38.3 (12.4)
Median 37.0 38.0 37.0
Range (min, max) 18, 64 18, 65 18, 65
Gender, n (%)
Male 101 (58.4) 121 (66.1) 222 (62.4)
Female 72 (41.6) 62 (33.9) 134 (37.6)
Race, n (%)
White 98 (56.6) 102 (55.7) 200 (56.2)
Asian 73 (42.2) 78 (42.6) 151 (42.4)
Other 2 (1.2) 3 (1.6) 5 (1.4)
Weight (kg)
Mean (SD) 69.1 (15.9) 71.0 (17.1) 70.1 (16.5)
Median 68.0 69.0 68.0
Range (min, max) 37, 120 37, 115 37, 120
BMI (kg/m2)
Mean (SD) 24.3 (4.3) 24.9 (5.2) 24.6 (4.8)
Median 23.8 24.1 23.9
Range (min, max) 15.8, 37.1 14.7, 43.8 14.7, 43.8
Psychiatric diagnosis, n (%)
Most recent episode manic 159 (91.8) 173 (94.5) 332 (93.3)
Most recent episode mixed 14 (8.1) 10 (5.5) 24 (6.7)
Rapid cycling, n (%)
Yes 3 (1.7) 5 (2.7) 8 (2.2)
No 170 (98.3) 178 (97.3) 348 (97.8)
Time since first diagnosis of acute mania, years
Mean (SD) 7.1 (6.6) 7.8 (7.0) 7.5 (6.8)
Time since first mania/mixed episode, years
Mean (SD) 7.2 (6.6) 8.1 (7.0) 7.7 (6.8)
Total number of mania/mixed episodes in the
past year, n (%)
0 56 (32.4) 56 (30.6) 112 (31.5)
1 88 (50.9) 88 (48.1) 176 (49.4)
≥ 2 29 (16.8) 39 (21.3) 68 (19.1)
Previous medication use, n (%)
Lithium 4 (2.3) 2 (1.1) 6 (1.7)
Quetiapine 8 (4.6) 17 (9.3) 25 (7.0)
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significant between-group difference (Table 2).
Safety and tolerability assessments
The incidence of TEAEs was 63.0% in the add-on lithium
and 48.1% in the add-on placebo group. Tremor, somno-
lence, dizziness, diarrhea, and vomiting occurred at higher
rates in the add-on lithium than add-on placebo group(Table 3). Treatment-emergent adverse events in both
groups were mostly mild to moderate in intensity.
Adverse events led to discontinuation in a greater pro-
portion of patients in the add-on placebo than add-on lith-
ium group (n = 13 (7.1%) and n = 6 (3.5%), respectively).
Psychiatric disorders, including mania, were the most
common AE leading to discontinuation, reported in two
patients in the add-on lithium and seven patients in the
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Patient numbers at each study visit:
Figure 2 Mean change in YMRS total score (with 95% CIs) from
baseline (observed case data, ITT set).
Table 2 Mean changes from baseline to day 43 in
primary and secondary efficacy measures (ITT set)
Measure Quetiapine XR +
Lithium (n = 173)
Quetiapine XR +
Placebo (n = 176)
Young Mania Rating Scale (YMRS) total score
LS Mean change (SE)
(MMRM)
−22.8 (0.71) −20.1 (0.71)
Mean difference (95% CI) −2.69 (−4.09, −1.29)
p-value <0.001
Mean change (SD) (OC) −22.6 (7.24) −20.4 (7.64)
n at day 43 149 147
Clinical Global Impressions Bipolar–Severity (CGI-BP-S)
LS Mean change
(SE) (MMRM)
−2.5 (0.08) −2.2 (0.08)
Mean difference (95% CI) −0.24 (−0.43, −0.04)
p-value 0.017
Mean change (SD) (OC) −2.5 (0.99) −2.3 (1.00)
n at day 43 149 147
Clinical Global Impressions Bipolar-Change (CGI-BP-C)
LS Mean (SE) (MMRM) 1.7 (0.09) 1.9 (0.09)
Mean difference (95% CI) −0.20 (−0.37, −0.03)
p-value 0.020
Mean (SD) (OC) 1.7 (0.69) 1.9 (0.85)
n at day 43 149 147
Positive and Negative Syndrome Scale (PANSS) total score
LS Mean change (SE)
(MMRM)
−19.2 (0.91) −15.6 (0.91)
Mean difference (95% CI) −3.7 (−5.74, −1.63)
p-value <0.001
Mean change (SD) (OC) −19.8 (12.34) −16.1 (10.82)




−8.1 (0.32) −7.0 (0.32)
Mean difference (95% CI) −1.1 (−1.85, −0.39)
p-value 0.003
Mean change (SD) (OC) −8.1 (4.47) −7.1 (4.54)




−7.1 (0.28) −5.9 (0.28)
Mean difference (95% CI) −1.2 (−1.77, −0.61)
p-value <0.001
Mean change (SD) (OC) −7.3 (3.60) −5.9 (3.77)
n at day 43 148 147
Montgomery-Åsberg Depression Rating Scale (MADRS) total score
LS Mean change
(SE) (MMRM)
−4.8 (0.37) −4.1 (0.37)
Mean difference (95% CI) −0.6 (−1.36, 0.07)
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cluded mania (n = 3 patients) and gastroenteritis (n = 1)
in the add-on lithium group and mania (n = 6), aggression
(n = 1), hostility (n = 1), and no therapeutic response (n =
1) in the add-on placebo group. The SAEs of emergent
mania led to study discontinuation in two patients in
the add-on lithium and six patients in the add-on placebo
group.
Incidences of TEAEs potentially related to EPS were
16.8% in the add-on lithium and 6.6% in the add-on pla-
cebo group, including tremor in 15.6% and 4.9% of patients,
respectively. All these TEAEs were mild to moderate in in-
tensity. Two TEAEs (tremor and dystonia) resulted in study
discontinuation in the add-on placebo group. The majority
of patients showed either improvement or no change in
EPS severity during the study, assessed by SAS, AIMS, and
BARS scores. For example, SAS score was improved in
11.6% and 8.2% of the add-on lithium and placebo-add
groups, respectively, unchanged in 67.1% and 75.4% and
worsened in 15.6% and 9.8%, respectively, at day 43. No
patients initiated anticholinergic medication for new-onset
EPS.
No TEAEs potentially related to suicidality were reported
during the study. Columbia-Suicide Severity Rating Scale
Table 2 Mean changes from baseline to day 43 in
primary and secondary efficacy measures (ITT set)
(Continued)
p-value 0.077
Mean change (SD) (OC) −5.0 (4.84) −4.5 (3.56)
n at day 43 149 147
ITT, intent to treat; LS, least squares; MMRM, mixed-model repeated measures;
OC, observed cases. A negative change in score indicates improvement, with
the exception of Clinical Global Impressions Bipolar-Change, where a positive
change in score indicates improvement. Significant p-values shown in bold.
Figure 3 Mean changes in YMRS item scores from baseline (ITT set, M
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and one with suicidal ideation in the add-on lithium group.
Columbia-Suicide Severity Rating Scale and C-CASA as-
sessments at end of treatment indicated that no patients
had any type of suicidal ideation in either group. Rates of
emergent depression were low in both add-on lithium
(1.2%) and add-on placebo (0.5%) groups.
Among other TEAEs of special interest, there were no
reported events potentially related to diabetes mellitus,
neutropenia, or QTc prolongation. No clinically meaning-
ful between-group differences were reported in inci-
dences of physical examination, vital signs, hematology,
clinical chemistry, or urinalysis findings (Additional file 1:
Table S2). There were no notable between-group dif-
ferences in mean changes in liver function parameters,MRM analysis).
Table 3 Incidence of treatment-emergent adverse events
(≥2% in any group; safety set)
Adverse event,
n (%)
Quetiapine XR + Lithium
(n = 173)
Quetiapine XR + Placebo
(n = 183)
Tremor 27 (15.6) 9 (4.9)
Somnolence 22 (12.7) 10 (5.5)
Constipation 16 (9.2) 16 (8.7)
Dry mouth 14 (8.1) 14 (7.7)
Dizziness 11 (6.4) 8 (4.4)
Insomnia 11 (6.4) 12 (6.6)
Headache 9 (5.2) 11 (6.0)
Pyrexia 10 (5.8) 9 (4.9)
Diarrhea 8 (4.6) 2 (1.1)
Vomiting 8 (4.6) 0
Sedation 5 (2.9) 3 (1.6)
Dysarthria 4 (2.3) 2 (1.1)
Nausea 5 (2.9) 3 (1.6)
Weight
increased
2 (1.2) 5 (2.7)
Increased
appetite
4 (2.3) 1 (0.5)
Patients with multiple events falling under the same category are counted
only once in that category.
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centration was greater in the add-on lithium than add-on
placebo group (mean (SD) –210.8 (488.1) mU/L vs. −116.9
(602.4) mU/L). A greater proportion of patients in the
add-on lithium group had weight gain ≥7% at end of treat-
ment compared with add-on placebo (8.0% vs. 4.7%).
Discussion
In this 6-week study, lithium as an add-on therapy to
quetiapine XR was significantly more effective than add-
on placebo for improving acute severe symptoms of bi-
polar mania, measured by change in YMRS total score at
day 43. Reductions in YMRS score of 22.8 and 20.1, re-
spectively, occurred in the add-on lithium and add-on
placebo groups, with a clinically relevant between-group
difference of 2.69 in favor of add-on lithium (p < 0.001).
Consistent with this primary efficacy measure, the second-
ary efficacy measures showed that add-on lithium signifi-
cantly improved a range of manic symptoms and the
overall severity of illness compared with add-on placebo.
The combination of quetiapine XR with lithium was
generally well tolerated, and reported AEs were consist-
ent with the known safety profiles of these medications
in bipolar disorder (Bowden 2000; Cutler et al. 2011;
Suppes et al. 2010). In agreement with studies of quetiapine
IR (Emsley et al. 2005), worsening of glycemic control
was not observed during quetiapine XR treatment com-
bined with lithium or placebo. Incidences of potentiallyEPS-related TEAEs were also consistent with studies
of quetiapine IR combined with lithium or divalproex
(Suppes et al. 2009; Yatham et al. 2004). Tremor, a known
side effect of lithium (Bowden 2000), occurred at higher
rates in the add-on lithium than add-on placebo group.
More patients in the add-on lithium than add-on placebo
group also had weight gain ≥7% at the end of treatment.
Add-on lithium was not associated with an altered rate of
switch to depressive symptoms, which occurred at low in-
cidences in both groups.
The current study is unique in comparing quetiapine
XR combined with lithium against quetiapine XR com-
bined with placebo. Direct comparison with previous
studies - which compared a mood stabilizer combined
with quetiapine IR against a mood stabilizer combined with
placebo - is not possible (Sachs et al. 2004; Suppes et al.
2009; Vieta et al. 2008a; Yatham et al. 2004), although
all these studies indicate the superior efficacy of com-
bination therapy versus monotherapy. In the earlier stud-
ies, quetiapine IR combined with a mood stabilizer was
significantly more effective than mood stabilizer alone in
acute mania (Sachs et al. 2004; Yatham et al. 2004) and in
the prevention of recurrent mood disorder (Suppes et al.
2009; Vieta et al. 2008a). A post hoc analysis of the two
maintenance studies (Suppes et al. 2009; Vieta et al.
2008a) demonstrated that quetiapine IR combined with
lithium was associated with a 68% reduction in risk of
recurrence of a mood event (manic, depressive, or mixed)
compared with placebo and lithium (p < 0.001), while
quetiapine combined with divalproex reduced recurrence
risk by 72% compared with placebo and divalproex (p <
0.001) (Suppes et al. 2013). A second post hoc analysis of
the maintenance studies showed that quetiapine combined
with mood stabilizer (vs. mood stabilizer alone) signifi-
cantly reduced the risk of recurrence of a mood event,
whether the index episode was manic, depressive, or mixed
(Vieta et al. 2012) (p ≤ 0.001, all). Quetiapine (IR or XR) in
combination with lithium or divalproex is also associated
with quality-adjusted life expectancy and cost-effectiveness
benefits relative to maintenance treatment with mood sta-
bilizers alone (Plosker 2012). Together, these findings may
provide a rationale for initiating treatment with combined
quetiapine XR and lithium in patients with severe acute
manic symptoms, rather than escalating the dose of mono-
therapy up to the highest dose approved, and hence also
for subsequent use of this combination as maintenance
treatment to prevent recurrence.
Notable features of this study include the initiation of
medications (quetiapine XR and lithium or placebo) con-
currently at the start of the study, which reflects manage-
ment of severe acute mania in practice. To demonstrate
efficacy for combination therapy in this setting is challen-
ging, when compared with study of patients who show
partial response to monotherapy. This study also required
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assurance on the reliability of YMRS and other scoring at
baseline.
Direct comparison of the quetiapine XR and lithium
combination versus other combination therapies in acute
mania is hampered by the limited availability of other stud-
ies and differences in study design, duration, and patient
population. Most studies report superior efficacy for com-
binations versus monotherapy (measured as symptom
control, speed of onset, or relapse prevention), but also
increased rates of AEs and related discontinuations
(Geoffroy et al. 2012). For example, when compared with
a mood stabilizer alone, combinations including a mood
stabilizer and olanzapine or asenapine are associated with
weight gain, combinations including aripiprazole lead
to greater risk of akathisia, and combinations including
quetiapine are associated with increased somnolence
(Geoffroy et al. 2012; Sachs et al. 2004; Szegedi et al. 2012;
Tohen et al. 2002; Vieta et al. 2008b; Yatham et al. 2004).
While the quetiapine XR and lithium combination in the
current study was associated with elevated rates of tremor
and somnolence when compared with quetiapine alone,
the combination was generally well tolerated and rates
of treatment-related discontinuations were below add-on
placebo-group levels.
This study raises a number of questions that would re-
quire further investigation. Add-on lithium showed sig-
nificant benefits despite a high proportion of patients
(approximately 65%) having serum lithium levels outside
the target range. The target lithium range selected (0.8
to 1.2 mEq/L) was based on evidence for the efficacy of
lithium as monotherapy in bipolar disorder (Goodwin and
Jamison 2007). Post hoc analyses in the current study re-
ported greater efficacy (assessed as YMRS score change,
response rate, and remission rate) for add-on lithium
versus add-on placebo at a lithium level ≥6 mEq/L, but
not <6 mEq/L. These data are consistent with an earlier
study that reported significant efficacy against manic symp-
toms for lithium monotherapy versus placebo at higher
(0.72 and 0.5 mEq/kg/day) but not lower (0.24 mEq/kg/
day) lithium doses (Stokes et al. 1976). It may also be
conjectured that the use of lower quetiapine doses in the
add-on lithium than add-on placebo group (mean modal
623.1 mg/day vs. 669.9 mg/day) contributed to reduce the
between-group difference in YMRS score. Investigators
may have judged that there was no requirement to in-
crease the quetiapine dose in a substantial proportion of
patients due to the effective control of manic symptoms
achieved by the addition of blinded lithium. Furthermore,
the lower doses of quetiapine used in the add-on lithium
group may have contributed to the beneficial side effect
profile of combination therapy observed in this study.
The study design excluded patients with a known lack
of response to lithium or quetiapine, although only 1.7%and 7.0%, respectively, of the study population were
treated with lithium and quetiapine previously. The benefits
of combination therapy in lithium nonresponders are
therefore unknown from this study, although other studies
(Hardoy et al. 2005; Yatham et al. 2004) have suggested
that lithium nonresponders may benefit from combination
therapy with quetiapine and lithium. The pharmacological
rationale for combining quetiapine and lithium also re-
mains to be confirmed, although it may be conjectured that
the mechanisms of action of quetiapine (Nemeroff et al.
2002; Nord et al. 2011) and lithium (Quiroz et al. 2010;
Shim et al. 2012) are complementary and additive as com-
bination therapy.Conclusions
Add-on lithium enhanced the efficacy of quetiapine XR in
patients with acute bipolar I mania, without compromising
safety and tolerability.Additional file
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